Hyperglycemia during critical illness.
BACKGROUND
We sought to review the literature describing the benefits of tight glycemic control in critically ill patients, comparing outcome differences in subgroup populations.


METHODS
We searched PubMed for relevant literature on the topic of hyperglycemia and its management in the intensive care unit.


RESULTS
Overwhelming evidence in both surgical and medical patients conclusively demonstrates that hyperglycemia is a marker of severity of illness and is also an independent determinant of bad outcome, largely from infectious complications. Randomized trial evidence, in conjunction with historically controlled trials, supports the use of intensive insulin therapy and euglycemic control in critically ill patients, with nondiabetics possibly benefiting even more than diabetic patients. Euglycemia is best achieved, and hypoglycemia attenuated, through use of a protocolized approach. Further elaboration as to what threshold range defines euglycemia in patient subpopulations is needed and what pitfalls must be avoided in this practice. Development of continuous blood glucose monitoring has started and will someday be incorporated into routine practice in the same way that continuous electrocardiographic monitoring and pulse oximetry are standards of care in the intensive care unit.


CONCLUSIONS
Hyperglycemia is a predictor of death and complications in critically ill patients. Early aggregated study results show that control of hyperglycemia improves outcomes. Well-designed studies involving thousands of patients have started to better elucidate the concomitant promoters of hyperglycemia and to better quantify the benefits from tight glycemic control.
Nasraway
Stanley A
SA
Department of Surgery, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA. Snasraway@tufts-nemc.org
D015415:Biomarkers; D001786:Blood Glucose / Q000378:metabolism*; D003422:Critical Care / Q000379:methods; D016638:Critical Illness; D006801:Humans; D006943:Hyperglycemia / Q000150:complications* / Q000401:mortality; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D007362:Intensive Care Units; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin